Aprea Therapeutics
APRE
APRE
23 hedge funds and large institutions have $3.07M invested in Aprea Therapeutics in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
23
Holders Change
-3
Holders Change %
-11.54%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$51.6K |
| 2 |
SCM
Sio Capital Management
New York
|
+$4.68K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$2.93K |
| 4 |
LPL Financial
San Diego,
California
|
+$1.69K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$852 |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$61.4K |
| 2 |
EAM
Exome Asset Management
New York
|
-$59.1K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$14.4K |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$11.7K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.72K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
EAM
26
Exome Asset Management
New York
| – | -$59.1K | -28,972 | Closed |
|
27
JPMorgan Chase & Co
New York
| – | -$20 | -10 | Closed |
|